Sharemaestro Newsreel

UFP Technologies, Inc. (UFPT) Stock Analysis: Exploring the 9.23% Potential Upside in the Booming Medical Devices Sector

UFP Technologies, Inc. (UFPT) is presented as an appealing investment opportunity in the medical devices sector, boasting a $2.52 billion market cap and strong revenue growth of 15.10%. The company specializes in designing and manufacturing solutions for various medical devices, including advanced wound care …

Tenon Medical Announces Reverse Stock Split to Maintain Listing

Tenon Medical, Inc. (TNON) has announced a 1-for-35 reverse stock split, effective August 10, 2026, to meet Nasdaq's minimum $1.00 per-share requirement and maintain its listing. The company specializes in medical devices for sacro-pelvic disorders, marketing the Catamaran and SImmetry+ SI Joint Fusion Systems. …

PRCT Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements …

LivaNova PLC (LIVN) employee stock rights lead to 2,675-share sale

LivaNova PLC has reported a planned sale of 2,675 shares of common stock, stemming from the exercise of employee stock appreciation rights. The transaction, valued at $209,942.40, is scheduled for August 11, 2026, and will be executed through Merrill Lynch as a broker-assisted cashless …

Bio-Rad (BIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 5 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Ruben ArguetaChief Executive Officer - Norman SchwartzPresident and Chief Operating Officer - Jonathan DiVincenzoExecutive Vice President and Chief Financial Officer - Roop Lakkaraju …

Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments

Cytek Biosciences is seeing its recurring revenue, from service and reagent sales, grow as it expands its global installed base of instruments and introduces new cell-analysis platforms. Recurring revenue now accounts for 35% of total sales on a trailing 12-month basis, up from 32% …

Varex Imaging (VREX) Stock Price Hints Caution After Profit Rebound

Form 8K Neuronetics Inc For: 11 August By Investing.com

This article reports on Neuronetics Inc.'s Form 8K filing for August 11, without providing further details on the content of the filing. It is a brief announcement from Investing.com, typical of financial news outlets reporting SEC filings. The piece primarily serves as a placeholder …

NeuroPace Q2 2026 slides: 21% RNS growth, $55B+ market opportunity

NeuroPace reported strong Q2 2026 results with 21.3% year-over-year revenue growth in its RNS System business, driven by increasing adoption in the adult focal epilepsy market. Despite beating analyst estimates, shares declined due to ongoing losses and regulatory uncertainty surrounding its idiopathic generalized epilepsy …

NeuroPace Raises FY26 Sales Guidance Above Estimates

NeuroPace Inc. has increased its sales guidance for fiscal year 2026 to $99.5 million-$101.5 million, surpassing the consensus estimate of $99.913 million. This upward revision indicates strong demand for its RNS System and improved visibility into recurring revenue, demonstrating the company's confidence in its …

Tactile Systems Technology (TCMD) Stock Price Drop Defies Profit Momentum

Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up

Alamar Biosciences (ALMR) shares surged 31% after reporting an 82% increase in second-quarter revenue, primarily driven by a 147% surge in consumable sales. Consumables now account for 52.6% of revenue, boosting gross margin to 60%. Despite continued operating losses, the company's strong revenue growth …

Mobia Medical forecasts $54M-$56M 2026 revenue, citing 69%-75% growth target

Earnings Call Insights: Mobia Medical (MOBI) Q2 2026 MANAGEMENT VIEW * "We are pleased to welcome you to Mobia Medical's first earnings call as a public company. In May, we successfully completed our initial public offering, raising $134 million in net proceeds" (CEO, President …

NNOX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Nano-X Imaging Ltd. to Contact the Firm Today!

Bronstein, Gewirtz & Grossman, LLC is issuing a final reminder to stockholders of Nano-X Imaging Ltd. (NASDAQ:NNOX) about a class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. and its officers made false and misleading statements regarding the company's operations and prospects between …

Axogen, Inc. SEC Filing (Aug 11, 2026)

This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 11, 2026, detailing a proposed sale of 13,353 common shares with an aggregate market value of $643,881.66 through Morgan Stanley Smith Barney LLC. The securities were acquired on the …

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace, Inc. reported its second-quarter 2026 financial results, with total revenue reaching $22.8 million and RNS revenue growing 21% to $22.5 million. The company raised its full-year 2026 total revenue guidance to $99.5 million to $101.5 million and improved its Adjusted EBITDA loss. NeuroPace …

Earnings call transcript: Mobia Medical posts strong Q2 2026 growth, stock flat

Mobia Medical reported strong Q2 2026 revenue growth of 102% year-over-year, reaching $13.5 million, driven by increased adoption of its Vivistim stroke therapy. Despite the significant revenue increase, the company posted a net loss of $21.0 million and its stock remained flat after hours. …

Abbott Laboratories (ABT) schedules NYSE sale of stock from vested awards

Abbott Laboratories (ABT) has filed a Form 144 indicating a planned sale of 5,850 common shares through UBS Financial Services on or after August 11, 2026, on the NYSE. The shares originate from vested restricted stock awards granted on February 27, 2026, totaling 1,960, …

UnitedHealth (UNH) Stock Slips As Medical Cost Fears Mute Profit Rebound

Spectral AI (NASDAQ:MDAI) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Spectral AI (NASDAQ:MDAI) announced quarterly earnings, reporting a loss of $0.13 per share, beating the consensus estimate by $0.01. Despite revenue of $3.52 million falling short of analysts' forecasts, the company received FDA clearance for its DeepView burn-assessment system and reiterated its full-year revenue …

NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Koninklijke Philips N.V. (PHG) stock price, news, quote and history

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT [https://seekingalpha.com/symbol/EAT]) * Amcor plc (AMCR [https://seekingalpha.com/symbol/AMCR]) * Jumia Technologies AG (JMIA [https://seekingalpha.com/symbol/JMIA]) Other earnings slated for release before Wednesday's …

Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com

This article reports that Vivos Therapeutics Inc filed a Form 8K on August 11. It's a brief financial news item from Investing.com, noting the filing for the company with the stock symbol VVOS.

Owlet (NYSE:OWLT) Posts Earnings Results, Beats Estimates By $0.29 EPS

Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours

NeuroPace reported Q2 2026 results that exceeded Wall Street expectations for both earnings and revenue, but its shares fell in after-hours trading. The company posted a narrower adjusted loss and 17% revenue growth, driven by strong RNS System sales. Management raised full-year revenue and …

Vivos Therapeutics Strengthens IP for Sleep Apnea Devices

PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) CEO Mark Van Oene was granted 1.97 million stock options and 489,130 Restricted Stock Units (RSUs) on August 10, 2026. The stock options have an exercise price of $1.15 per share and vest over 36 monthly installments, while …

Does Strong Q1 Results And VASCADE Data Shift The Bull Case For Haemonetics (HAE)?

Haemonetics Corporation reported stronger-than-expected Q1 results with increased sales and diluted EPS, along with positive new Emory University study data reinforcing the safety and efficiency of its VASCADE MVP XL venous vascular closure system. These developments, particularly the VASCADE data, are seen as significant …

Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript

Neuropace earnings beat by $0.03, revenue topped estimates

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace, Inc. (NPCE) reported a Q2 loss of $0.18 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and showing an improvement from a $0.26 loss a year ago. The company also surpassed revenue estimates, posting $22.83 million against a consensus of …

Stryker’s (SYK) Comeback Quarter Looks Great, But At What Cost?

Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that …

Insulet Corp. stock outperforms competitors on strong trading day

Insulet Corp. (PODD) saw its stock rise 1.30% to $144.70 on Tuesday, marking its fourth consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index and Dow Jones Industrial Average both experienced declines.

Earnings call transcript: SINTX posts Q2 2026 revenue growth but shares slip after hours

Sintx Technologies reported significant revenue growth of 199% year-over-year in Q2 2026, reaching $452,000, driven by increased product sales and improved gross margins. The company highlighted over $3.2 million in new purchase orders for contract manufacturing and initial commercial revenue from its SINAPTIC Foot …

Owlet, Inc. (OWLT) Q2 Earnings and Revenues Beat Estimates